Biocon Biologics Ltd. - The Bradford Era

Press Releases

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

Biocon Biologics Ltd.

April 10, 2025

BRIDGEWATER, N.J.and BENGALURU,India , April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: B...

Press Releases

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

Biocon Biologics Ltd.

March 7, 2025

BRIDGEWATER, N.J. , andBENGALURU,India , March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL) ,a fully integrated global biosimilars company and ...

Press Releases

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

Biocon Biologics Ltd.

March 6, 2025

BRIDGEWATER, N.J. and PETERSBURG, Va. and BENGALURU, India , March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL) ,a fully integrated global biosi...

Press Releases

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States

Biocon Biologics Ltd.

February 24, 2025

BRIDGEWATER, N.J.andBENGALURU, India , Feb. 24, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL) ,a fully integrated global biosimilars company and su...

Press Releases

Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biocon Biologics Ltd.

January 9, 2025

BRIDGEWATER, N.J. , andBENGALURU,India , Jan. 9, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL) ,a fully integrated global biosimilars company and su...

Press Releases

U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 Biosimilar to J&J’s Stelara® (Ustekinumab)

Biocon Biologics Ltd.

December 2, 2024

BRIDGEWATER, N.J. and BENGALURU, India , Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL) ,a fully integrated global biosimilars company and su...